<DOC>
	<DOCNO>NCT02666378</DOCNO>
	<brief_summary>This research study evaluate use Cardiac Magnetic Resonance Imaging ( CMR ) method detect early sign damage heart associate adjuvant therapy anthracycline ( doxorubicin ) -based combination chemotherapy follow treatment herceptin ( trastuzumab treatment ( HER+ ) breast cancer .</brief_summary>
	<brief_title>Imaging Markers Subclinical Cardiotoxicity Breast Cancer</brief_title>
	<detailed_description>HER 2 breast cancer show respond well adjuvant therapy doxorubicin follow trastuzumab . One side effect observe woman receive treatment heart complication heart muscle weaken longer able pump sufficient amount blood throughout body . This complication lead follow symptom : shortness breath exertion , swollen ankle foot , lack energy reduce capacity carry day-to-day activity . This research study focus identify early sign heart complication use CMR , may allow preventative treatment option make available future .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>age &gt; 18 year histologic diagnosis HER2+ breast carcinoma schedule receive adjuvant therapy consist doxorubicin follow trastuzumab able give inform consent . prior cardiovascular disease atrial fibrillation baseline screen echo LVEF â‰¤ 50 contraindication contrast CMR include eGFR &lt; 30 mls/min/1.73m2 prior chemotherapy radiotherapy uncontrolled serious concurrent illness pregnancy breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HER-2 Positive Breast Cancer</keyword>
</DOC>